Real-World Outcomes of Hypomethylating Agents and Venetoclax Combination Therapy in AML and Myelodysplastic Syndrome in Pakistan
PURPOSEThe combination of venetoclax (VEN) and a hypomethylating agent (HMA) is a standard of care for patients with AML and higher-risk myelodysplastic syndromes (MDS). However, real-world outcomes data from low- and middle-income countries are scarce, where constraints in advanced diagnostics, fin...
Gardado en:
| Principais autores: | , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Society of Clinical Oncology
2026-05-01
|
| Series: | JCO Global Oncology |
| Acceso en liña: | https://ascopubs.org/doi/10.1200/GO-25-00317 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|